New joint venture with PREV PreveCeutical Medical Inc. (C-PREV) - News Release
ORIGINAL: PreveCeutical Applies its Proprietary Extraction Protocol for Medical Cannabinoids to Two Additional Cannabis Strains
2018-11-05 09:00 ET - News Release
PREV Close 2018-11-02 C$ 0.085
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in connection with its soluble gel drug delivery research and development program (the "Sol-gel Program"), it has now optimised the conditions for extracting cannabinoids from two additional cannabis strains provided by the Company's licensed producer (LP) partner, Aurora Cannabis Inc. ("Aurora").
The two strains possess discrete cannabinoid compositions that are consistent with Aurora's specifications, exemplifying the accuracy and precision of PreveCeutical's proprietary extraction protocol (the "Extraction Protocol") in quantifying cannabinoids present in plant extracts. For further information on the development of the Extraction Protocol, see the Company's news release dated September 4, 2018.
PreveCeutical's Chief Research Officer, Dr. Harendra Parekh stated, "This is an important verification of our efforts in reproducibly extracting and identifying cannabinoid and THC-rich fractions from plant material, leading to distinct fingerprints for a given strain. This development puts us in a good position for generating a standard operating procedure, encompassing the fingerprinted extracts in Sol-gel formulations."
PreveCeutical's Chairman, Chief Executive Officer and President, Stephen Van Deventer stated, "We are excited with how the fingerprinting of the cannabis strains is progressing. With the CBD Sol-gel formulations and applicator development on track, this brings us one step closer to getting the Sol-gel nose-to-brain delivery system to market."
PreveCeutical plans to fingerprint two more cannabis strains by 2019, which will bring the total number of distinct fingerprinted cannabis strains in the Company's target cannabinoid concentration range to five. The Company intends to use the fingerprints to generate a range of cannabinoid-based Sol-gel formulations (each, a "CBD Sol-gel Formulation"), each with a distinct, well-defined cannabinoid composition profile.
The CBD Sol-gel Formulations, when used with the Company's custom Sol-gel applicator (the "Sol-gel Applicator"), are expected to facilitate prolonged delivery of cannabinoids to patients' central nervous systems. The Company's medicinal cannabis division expects to be able to offer a broad product range that can be tailored to specific medical conditions. For example, PreveCeutical is currently developing a CBD Sol-gel Formulation with a cannabinoid composition designed to decrease patient anxiety (see news release dated August 8, 2018).
The Sol-gel Applicator is currently in development. The Company's research partner, The University of Queensland, has received several prototypes for the Sol-gel Applicator from the Company's manufacturer, and has been assessing their performance in the Sol-gel Program.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company's website.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: https://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.